Accelr8 and BD Enter Agreement for Rapid Bacterial Diagnostics

Accelr8 Technology Corp. (Denver, CO, USA) and Becton, Dickinson and Company (BD; Franklin Lakes, NJ, USA) have agreed in principle to terms of an agreement with respect to Accelr8's BACcel rapid bacterial diagnostic system.

According to the agreement, BD is funding an 18-month milestone project that started April 1, 2008. BD will also have the option to license the technology for product development, manufacturing, and commercialization for the clinical diagnosis of infectious diseases.

Accelr8 Technology is a developer of materials and instrumentation for advanced applications in medical instruments, basic research, drug discovery, and bio-detection. The company is developing the BACcel rapid diagnostic system based on its surface coatings, assay processing, and detection technologies. In addition, Accelr8 licenses certain of its proprietary technology for use in applications outside of Accelr8's own products.

According to Accelr8's president, David Howson, "BD leads the industry in clinical microbiology, with broad product offerings for classical microbiology as well as molecular diagnostics. We are excited to work with BD as we move into our next phase of BACcel development.”

BD is a global medical technology company that is focused on enhancing the diagnosis of infectious diseases, improving drug therapy, and advancing drug discovery. BD manufactures and sells diagnostic products, medical supplies, laboratory instruments, antibodies, reagents, and through three segments.


Related Links:
Accelr8 Technology
Becton, Dickinson and Company